Loading...
Docoh

Syros Pharmaceuticals (SYRS)

Utility
Inhibitors of cyclin dependent kinase 7 (CDK7)
26 Apr 22
The present invention provides, inter alia, compounds having the structures of formulas described herein; pharmaceutically acceptable salts, solvates, hydrates, tautomers, and isotopic forms thereof; and compositions (e.g., pharmaceutical compositions and kits) containing one or more of the foregoing.
Jason J. Marineau, Claudio Edmundo Chuaqui, Stephane Ciblat, Anzhelika Kabro, Henri Piras, Kenneth Matthew Whitmore, Kate-Lyn Lund
Filed: 16 Jan 19
Utility
Compounds for the modulation of MYC activity
15 Mar 22
Jason J. Marineau, Kevin Sprott, Stephane Ciblat, Christopher Roberts, Yi Zhang, Francis Beaumier, Luce Lépissier, Boubacar Sow, Peter B. Rahi, Robin Larouche-Gauthier, Lauren Berstler
Filed: 8 Sep 17
Utility
Compounds for the Modulation of Myc Activity
17 Feb 22
Jason J. Marineau, Peter B Rahl, Kevin Sprott, Stephane Ciblat, Boubacar Sow, Robin Larouche-Gauthier, Lauren Berstler, Christopher Roberts, Yi Zhang, Francis Beaumier, Luce Lépissier
Filed: 25 Aug 21
Utility
Inhibitors of Cyclin Dependent Kinase 7 (CDK7)
6 Jan 22
The present invention provides, inter alia, compounds having the structures of formulas described herein; pharmaceutically acceptable salts, solvates, hydrates, tautomers, and isotopic forms thereof; and compositions (e.g., pharmaceutical compositions and kits) containing one or more of the foregoing.
Jason J. Marineau, Claudio Edmundo Chuaqui, Stephane Ciblat, Anzhelika Kabro, Henri Piras, Kenneth Matthew Whitmore, Kate-Lyn Lund, Michael Bradley
Filed: 16 Jan 19
Utility
Methods of Treating Cancer In Biomarker-identified Patients with Non-covalent Inhibitors of Cyclin-dependent Kinase 7 (CDK7)
30 Dec 21
The present invention relates to methods of identifying patients suffering from various types of cancer who are more likely to respond to treatment with a CDK7 inhibitor conforming to structural Formula (I), (Ia), a species thereof, or a specified form thereof (as described herein), either when administered or used alone or in combination with a second therapeutic agent (e.g., another anti-cancer therapy).
John Graeme Hodgson, Liv Helena Johannessen
Filed: 1 Nov 19
Utility
Inhibitors of Cyclin-dependent Kinase 7 (CDK7)
30 Dec 21
The present invention provides various compositions, including compounds of Formula (I) or (Ia), or a species thereof, and pharmaceutically acceptable salts, solvates (e.g., hydrates), stereoisomer, tautomers, isotopic and other specified forms thereof.
Jason J. Marineau, Michael Bradley, Claudio Chuaqui, Stephane Ciblat, Anzhelika Kabro
Filed: 1 Nov 19
Utility
Inhibitors of Cyclin Dependent Kinase 7 (CDK7)
9 Dec 21
The present invention provides, inter alia, compounds having the structures of formulas described herein; pharmaceutically acceptable salts, solvates, hydrates, tautomers, and isotopic forms thereof; and compositions (e.g., pharmaceutical compositions and kits) containing one or more of the foregoing.
Jason J. Marineau, Claudio Edmundo Chuaqui, Stephane Ciblat, Anzhelika Kabro, Henri Piras, Kenneth Matthew Whitmore, Kate-Lyn Lund
Filed: 16 Jan 19
Utility
Compounds for the modulation of Myc activity
21 Sep 21
Jason J. Marineau, Peter B. Rahl, Kevin Sprott, Stephane Ciblat, Boubacar Sow, Robin Larouche-Gauthier, Lauren Berstler, Christopher Roberts, Yi Zhang, Francis Beaumier, Luce Lépissier
Filed: 3 Jun 16
Utility
Methods of Stratifying Patients for Treatment with Retinoic Acid Receptor-alpha Agonists
16 Sep 21
Described herein are methods that define cellular populations that are sensitive to RARA agonists and identify patient populations that will benefit from treatment with RARA agonists.
Michael Robert McKeown, Christopher M. Fiore, Matthew Lucas Eaton, Emily Payton Lee, Christian Fritz
Filed: 1 Jun 21
Utility
Compositions of cyclin dependent kinase 7 (CDK7) inhibitor
10 Aug 21
The present invention provides, in part, compositions comprising an inhibitor of cyclin-dependent kinase 7 (CDK7) and sulfobutyl ether-β-cyclodextrin.
Neera Jain
Filed: 3 Apr 18
Utility
Compounds for the Modulation of Myc Activity
22 Jul 21
Jason J. Marineau, Kevin Sprott, Stephane Ciblat, Christopher Roberts, Yi Zhang, Francis Beaumier, Luce Lépissier, Boubacar Sow, Peter B. Rahl, Robin Larouche-Gauther, Lauren Berstler
Filed: 30 Nov 20
Utility
Methods of stratifying patients for treatment with retinoic acid receptor-α agonists
6 Jul 21
Described herein are methods that define cellular populations that are sensitive to RARA agonists and identify patient populations that will benefit from treatment with RARA agonists.
Michael Robert McKeown, Christopher Fiore, Matthew Lucas Eaton, Emily Payton Lee, Christian Fritz
Filed: 14 Jan 19
Utility
Compounds for the Modulation of Myc Activity
24 Jun 21
Jason J. Marineau, Peter B. Rahl, Kevin Sprott, Stephane Ciblat, Boubacar Sow, Robin Larouche-Gauthier, Lauren Berstler, Christopher Roberts, Yi Zhang, Francis Beaumier, Luce Lépissier
Filed: 26 Jun 20
Utility
Heteroaromatic compounds useful for the treatment of proliferative diseases
22 Jun 21
Stephane Ciblat, Patrick Deroy, Nathanael Gray, Melissa Leblanc, Jason J. Marineau, Joel Moore, Kevin Sprott, Tinghu Zhang, M. Arshad Siddiqui, Anzhelika Kabro, Serge Leger, Stephanie Roy, Darby Schmidt, Dana K. Winter, Michael Bradley, Tom Miller
Filed: 5 Dec 18
Utility
Pyrrolotriazine compounds and methods of inhibiting TAM kinases
22 Jun 21
Described herein are compounds, methods of making such compounds, pharmaceutical compositions, and medicaments comprising such compounds, and methods of using such compounds to treat cancer.
David Moebius, Jason J. Marineau, Yi Zhang, Claudio Edmundo Chuaqui, Goran Malojcic, William Sinko, Huiping Amy Guan, Stephane Ciblat, Clint James, Amandine Xolin, Sylvain Bernard, Malay Doshi
Filed: 9 Oct 18
Utility
Pyrrolotriazine Compounds and Methods of Inhibiting Tam Kinases
20 May 21
Described herein are compounds, methods of making such compounds, pharmaceutical compositions, and medicaments comprising such compounds, and methods of using such compounds to treat cancer.
David Moebius, Jason J. Marineau, Yi Zhang, Claudio Edmundo Chuaqui, Goran Malojcic, William Sinko, Huiping Amy Guan, Stephane Ciblat, Clint James, Amandine Xolin, Sylvain Bernard, Malay Doshi
Filed: 22 Oct 20
Utility
Inhibitors of Cyclin-dependent Kinase 7 (CDK7)
4 Mar 21
Stephane Ciblat, Anzhelika Kabro, Melissa Leblanc, Serge Leger, Jason J. Marineau, Tom Miller, Stephanie Roy, Darby Schmidt, M. Arshad Siddiqui, Kevin Sprott, Dana K. Winter, Amy Ripka, Dansu Li, Guoli Zhang
Filed: 13 Nov 20
Utility
Methods of Stratifying Patients for Treatment with Retinoic Acid Receptor-alpha Agonists
16 Dec 20
The invention provides methods that define cellular populations that are sensitive to RARA agonists and identify patient subgroups that will benefit from treatment with RARA agonists.
Mei Wei Chen, Cindy Collins, Matthew Lucas Eaton, Matthew G. Guenther, Nan Ke, Jeremy Lopez, Michael Robert McKeown, David A. Orlando
Filed: 7 May 20
Utility
Inhibitors of cyclin-dependent kinase 7 (CDK7)
14 Dec 20
Stephane Ciblat, Anzhelika Kabro, Melissa Leblanc, Serge Leger, Jason J. Marineau, Tom Miller, Stephanie Roy, Darby Schmidt, M. Arshad Siddiqui, Kevin Sprott, Dana K. Winter, Amy Ripka, Dansu Li, Guoli Zhang
Filed: 14 May 19
Utility
Pyrrolotriazine Compounds and Methods of Inhibiting Tam Kinases
7 Oct 20
Described herein are compounds, methods of making such compounds, pharmaceutical compositions, and medicaments comprising such compounds, and methods of using such compounds to treat cancer.
David Moebius, Jason J. Marineau, Yi Zhang, Kathryn Austgen, Claudio Edmundo Chuaqui, Goran Malojcic, William Sinko, Huiping Amy Guan, Tracey Lodie Savoie, Stephane Ciblat, Clint James, Amandine Xolin, Sylvain Bernard, Malay Doshi
Filed: 8 Oct 18
Patents are sorted by USPTO publication date, most recent first